2026-525864-17-00招募中2 期
Trial to study the safety, pharmacokinetics and preliminary antitumour activity of ODM-216 in patients with cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 104
- 试验地点
- 27
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Trial Director
Scientific
Orion Corporation
研究点 (27)
Loading locations...
相似试验
已完成
1 期
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia2023-508819-23-00Hutchmed Ltd.22
已完成
1 期
Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR2023-507667-19-00Novartis Pharma AG24
招募中
1 期
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participants2024-512939-67-00Mindstate Design Labs Inc.68
已完成
1 期
A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic functionUrticariaAllergic rhinitis2022-500774-34-00Noucor Health S.A.44
招募中
1 期
A study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)2023-503404-89-00Genentech Inc.45